Guidelines for Using Pentazocine in Pain Management

Indications and Clinical Use

Pentazocine can be administered orally or as an injection for moderate to severe pain, and is primarily used as an anesthetic adjunct or for treatment of moderate to severe pain, according to the Mayo Clinic Proceedings 1
The Society for Perioperative Assessment and Quality Improvement (SPAQI) recommends that pentazocine can be continued preoperatively, including on the day of surgical procedure, with careful consideration of its synergistic response with other anesthetics 1

There is no evidence suggesting that pentazocine significantly interferes with full mu opioid receptor agonists; rather, it acts synergistically when used together, as reported by the Mayo Clinic Proceedings 1
When continuing pentazocine perioperatively, clinicians should be aware of the synergistic response with other anesthetics, according to the Mayo Clinic Proceedings 2

Pentazocine should NOT be used in combination with pure opioid agonist drugs in patients dependent on opioids, as it may precipitate withdrawal, as stated in the Annals of Internal Medicine 3
Mixed agonist-antagonists like pentazocine are not recommended for cancer pain management due to their limited efficacy and risk of precipitating opioid withdrawal in patients receiving pure opioid agonists, according to the Journal of the National Comprehensive Cancer Network 4

In patients who are pentazocine addicts, if they use brown heroine dissolved in lemon juice, antifungal treatment should be added to their regimen, as recommended by the European Heart Journal 5
For patients with underlying valve lesions or left-sided cardiac involvement, additional antibiotic treatment against streptococci and enterococci should be considered, according to the European Heart Journal 5

For cancer pain, oral morphine is generally considered the first-line WHO level 3 opioid of choice rather than mixed agonist-antagonists like pentazocine, as reported by the British Journal of Cancer 6
Buprenorphine is not recommended as a WHO level 3 opioid since other opioids with better profiles have become available, according to the British Journal of Cancer 6